DEBIOPHARM
Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, announced today their participation in the 2024 World AMR conference from September 5th-6th in Philadelphia, Pennsylvania, USA. For the last decade, Debiopharm has been committed to developing new antimicrobials for patients by conducting research on a novel class of antibiotics that target hard-to-treat infections, caused by WHO priority pathogens. Now in its third year of sponsoring World AMR, Debiopharm is proud to support the conference’s mission to unite key decision-makers in AMR from international government bodies, policy organizations, and the healthcare sector to meet, discuss, and formulate initiatives to tackle the emerging threat of AMR effectively.
This year, Debiopharm’s Head of Global Value & Access, Jennifer Quinn, will present within the Impact, Policy and Awareness Track and lead a roundtable discussion on how to move the needle on fair reimbursement for antibiotics. Focused on actionable ways to leverage current reimbursement models, Jennifer’s presentation will outline a tangible framework for payer negotiations and discuss evidence needs for products that will reach the market before ‘pull incentives’ become available.
“We’re looking forward to open discussions and networking opportunities with public organizations and other infectious disease industry experts to put into place practical solutions to combat the reimbursement challenged that help to fuel AMR.” – Jennifer Quinn, Head of Global Value & Access.
World AMR 2023 Session details |
Congress agenda |
Speaker |
Presentation Sept. 5th 11:20AM EST
|
How can current reimbursement models be leveraged while waiting for 'pull incentives'? |
Jennifer Quinn, Head of Global Value & Access |
Roundtable discussion Sept. 5th 01:30PM EST
|
What data is needed to fit current payer evidence requirements and how can we generate it? |
Jennifer Quinn, Head of Global Value & Access |
About afabicin
Afabicin (Debio 1450) is Debiopharm’s first-in-class FabI inhibitor, selectively targeting Staphylococcus’ essential bacterial fatty acid biosynthesis pathway. Afabicin is active against Staphylococcus spp., of which methicillin-resistant Staphylococcus aureus (MRSA) strains are high on the WHO global priority pathogen list and deemed a “serious threat” by the CDC. Afabicin can be administered orally or intravenously. Promising results have been obtained in a comparative double-blind Phase 2 trial with afabicin in acute bacterial skin and skin structure infections. Currently, a global Phase 2 trial in bone and joint infections is being conducted, comparing afabicin to standard antibiotics.
About Debio 1453
Analogous to afabicin, the preclinical compound Debio 1453 is a potential first-in-class pathogen-specific drug targeting the essential bacterial fatty acid biosynthesis pathway. Debio 1453 has been developed as an oral drug with activity against. Neisseria gonorrhoeae, the bacteria causing the sexually transmitted disease gonorrhea. Untreated gonorrhea can cause serious and permanent health issues including infertility, ectopic pregnancy, long-term pelvic/abdominal pain, blindness in newborns and in rare cases also have a lethal outcome.
Debiopharm’s fight against antimicrobial resistance
Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing novel class antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing pathogen-specific antibiotics from early stage through phase II clinical research with afabicin, specifically targeting staphylococci. As a result of high selectivity, FabI inhibitors specifically target selected pathogens, and potentially preserve intestinal microbiota. Debiopharm’s FabI inhibitors meet all four WHO 2020 innovation criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.
For more information, please visit www.debiopharm.com
We are on X. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Sources
- Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet; 399(10325): P629-655.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827078184/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Civil Air Patrol Expands Fleet With 15 New Cessna Aircraft to Support Lifesaving and Community Missions15.12.2025 17:00:00 CET | Press release
Latest deliveries bring CAP’s Cessna fleet to more than 500 aircraft nationwide Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced today that Civil Air Patrol (CAP), the world’s largest operator of Cessna aircraft, is strengthening its national mission capabilities with an order for 15 additional piston-engine aircraft, including seven Cessna Skyhawk 172 and eight Cessna Skylane 182 models scheduled for delivery throughout 2026. The order follows recent deliveries of an additional two Cessna Skylane and one Cessna Turbo Stationair HD aircraft, expanding CAP’s fleet to more than 500 Cessna aircraft nationwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215613573/en/ Delivery of an additional two Cessna Skylane and one Cessna Turbo Stationair HD aircraft joins CAP’s fleet of more than 500 Cessna aircraft nationwide. Cessna aircraft are designed and produced by Textron Aviation. “Civil Air Patrol’s miss
Winston & Strawn and Taylor Wessing UK to Combine, Creating a Premier Transatlantic Law Firm15.12.2025 16:52:00 CET | Press release
Winston Taylor to build on shared vision and culture in establishing a transatlantic powerhouse for major litigation, critical transactions, strategic IP, and private wealth Winston & Strawn and Taylor Wessing’s UK-led business announced today their intention to combine, creating a premier transatlantic law firm that would operate under a new shared name, Winston Taylor. The combination responds to increasing client demand for seamlessly integrated US–UK–EU counsel for the businesses, people, and markets driving capital and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215914957/en/ The combination once final will unite two international firms with more than 400 years of combined history, complementary strengths, and a common vision to meet clients’ evolving global needs. The combined firm will include more than 1,400 lawyers, establishing one of the largest transatlantic firms whose footprint is primarily in
Despite Barriers, Financial Institutions are Clear About AI's Greatest Impact15.12.2025 16:32:00 CET | Press release
HTEC Finds AI is Everywhere in FSI, but Scaling Across the Enterprise Remains the Industry's Biggest Hurdle HTEC, a global AI-first provider of software and hardware design and engineering services, today released The State of AI in Financial Services & Insurance 2025, a first industry subset of its global research report in AI. This publication offers one of the clearest views to date into how financial institutions are adopting and scaling artificial intelligence. This industry-focused report analyzes insights from 250 C-suite leaders within financial services and insurance, drawn from HTEC’s broader global study of 1,529 C-suite executives—including CIOs, CTOs, CDOs, CPOs, CFOs, COOs, CEOs and CSOs—across Saudi Arabia, the UAE, the United Kingdom, the United States, Germany and Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215790717/en/ Executive Summary: The State of AI in Financial Services and Insurance 2025
Align Partners Sends Second Public Shareholder Letter to Coway, Urging Announcement of Revised Value-up Plan by January 30, 202615.12.2025 15:54:00 CET | Press release
Align identifies an inefficient capital structure and a sharp contraction in shareholder returns as core drivers of Coway’s undervaluationThe letter outlines seven key measures to strengthen capital allocation and governanceAlign urges Coway to announce a more concrete and enhanced Value-up Plan by January 30, 2026 Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Coway Co., Ltd. (“Coway”) since 2023 holding more than 4% of the Company’s outstanding shares through funds it manages or advises, announced that it has sent a second public shareholder letter to Coway’s Board of Directors. The letter calls for measures to address the company’s chronic undervaluation and enhance shareholder value. Align Partners has requested that Coway announce a revised corporate Value-up Plan reflecting these proposals by January 30, 2026. In the letter, Align Partners assessed Coway’s February 2025 plan as insufficient to address Coway’s persistent undervaluation and urged the Bo
Marathon Asset Management Provides Junior Capital Financing to EXALTA Group15.12.2025 15:00:00 CET | Press release
Marathon Asset Management (“Marathon”), a leading global credit manager with more than $24 billion of assets under management, is pleased to announce the closing of a junior capital financing to EXALTA Group (“EXALTA” or the “Company”), a portfolio company of Montagu. Marathon led the financing that supported the formation of EXALTA through the strategic merger of three Montagu-owned companies including Intech, Resolve Surgical Technologies, and Tyber Medical. The transaction marks one of many successful transactions for Marathon’s European Credit business in the healthcare sector, where the firm has a knowledge-based advantage with a dedicated Healthcare Finance business and specialized medical advisory board providing sector insight to middle market companies. EXALTA is a global leader in orthopaedic contract design and manufacturing for spine, trauma, extremities, sports medicine and enabling technology providing comprehensive solutions to OEMs within the medical technology industry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom